Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : PBLA save search
Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results
Published: 2024-03-26 (Crawled : 20:00) - globenewswire.com
PBLA | $0.4895 66K
|
Professional, Scientific, and T...
|
| O: 6.25%
H: 0.59%
C: -0.76%
business update financial results
Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024
Published: 2024-03-12 (Crawled : 20:00) - globenewswire.com
PBLA | $0.4895 66K
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
conference year
Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements
Published: 2024-02-15 (Crawled : 13:00) - globenewswire.com
PBLA | $0.4895 66K
|
Professional, Scientific, and T...
|
| O: 2.94%
H: 0.71%
C: -9.29%
nasdaq
Panbela Announces Closing of Approximately $9.0 Million Public Offering
Published: 2024-02-01 (Crawled : 12:00) - globenewswire.com
PBLA | $0.4895 66K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 0.0%
C: -9.35%
million offering
Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)
Published: 2024-01-30 (Crawled : 13:00) - globenewswire.com
PBLA | $0.4895 66K
|
Professional, Scientific, and T...
|
| O: 2.03%
H: 0.66%
C: -11.26%
sbp-101 association presentation cancer research
Panbela Announces Pricing of Approximately $9.0 Million Public Offering
Published: 2024-01-29 (Crawled : 12:00) - globenewswire.com
PBLA | $0.4895 66K
|
Professional, Scientific, and T...
|
| O: -64.4%
H: 1.97%
C: -2.63%
million offering
Panbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated Momentum
Published: 2024-01-25 (Crawled : 12:00) - globenewswire.com
PBLA | $0.4895 66K
|
Professional, Scientific, and T...
|
| O: 2.47%
H: 0.94%
C: -13.1%
momentum pancreatic aspire trial
Panbela Announces Publication of Clinical Data Titled: Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial
Published: 2024-01-18 (Crawled : 13:00) - globenewswire.com
PBLA | $0.4895 66K
|
Professional, Scientific, and T...
|
| O: -5.49%
H: 0.0%
C: -18.9%
publication trial therapy study
Panbela Announces 1-for-20 Reverse Stock Split Effective January 18, 2024
Published: 2024-01-16 (Crawled : 13:00) - globenewswire.com
PBLA | $0.4895 66K
|
Professional, Scientific, and T...
|
| O: -12.7%
H: 0.0%
C: -13.95%
Panbela Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $2.0 Million Gross Proceeds Priced At-the-Market
Published: 2023-12-21 (Crawled : 14:00) - globenewswire.com
PBLA | $0.4895 66K
|
Professional, Scientific, and T...
|
| O: -17.5%
H: 10.1%
C: -12.22%
million therapeutics
Panbela Therapeutics Announces US WorldMeds NDA Approval for Eflornithine (DFMO) in Pediatric Neuroblastoma
Published: 2023-12-18 (Crawled : 13:00) - globenewswire.com
PBLA | $0.4895 66K
|
Professional, Scientific, and T...
|
| O: 29.1%
H: 177.92%
C: 71.16%
approval therapeutics
Panbela Announces Publication of Abstract Titled: Evaluation of Myeloma Cell Lines Viability Following Administration of SBP-101 and DFMO Polyamine Inhibitors
Published: 2023-12-04 (Crawled : 13:00) - globenewswire.com
PBLA | $0.4895 66K
|
Professional, Scientific, and T...
|
| O: -3.96%
H: 0.0%
C: -9.72%
sbp-101 publication cell
Panbela Announces 2nd Independent Safety Review of the ASPIRE Registration Clinical Trial: Recommended Continuation with no Trial Modification
Published: 2023-11-29 (Crawled : 13:00) - globenewswire.com
PBLA | $0.4895 66K
|
Professional, Scientific, and T...
|
| O: 6.5%
H: 19.9%
C: -8.43%
continuation review aspire trial
Panbela Provides Business Update and Reports Q3 2023 Financial Results
Published: 2023-11-09 (Crawled : 21:00) - globenewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: -1.28%
H: 0.0%
C: 0.0%
PBLA | $0.4895 66K
|
Professional, Scientific, and T...
|
| O: 6.53%
H: 0.0%
C: -3.63%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: -0.32%
H: 0.0%
C: 0.0%
business update financial results
Panbela Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds Priced At-the-Market
Published: 2023-11-03 (Crawled : 12:00) - globenewswire.com
PBLA | $0.4895 66K
|
Professional, Scientific, and T...
|
| O: -27.19%
H: 11.96%
C: 4.12%
therapeutics
Panbela Announces Publication of Preclinical and Clinical Data Titled: Inhibition of Polyamine Biosynthesis Preserves β Cell Function in Type 1 Diabetes
Published: 2023-11-02 (Crawled : 12:00) - globenewswire.com
PBLA | $0.4895 66K
|
Professional, Scientific, and T...
|
| O: 46.89%
H: 5.97%
C: -18.8%
publication cell preclinical diabetes
Panbela Announces Validation of European Patent in UK, Italy, Germany, France, and Spain for Claims of a Novel Process for the Production of SBP-101
Published: 2023-10-31 (Crawled : 12:00) - globenewswire.com
PBLA | $0.4895 66K
|
Professional, Scientific, and T...
|
| O: 15.94%
H: 1.1%
C: -10.11%
sbp-101 patent
Acceptance of Polyamine Inhibitor CAR-T Combination Abstract for Online Publication
Published: 2023-10-25 (Crawled : 12:00) - globenewswire.com
PBLA | $0.4895 66K
|
Professional, Scientific, and T...
|
| O: -5.57%
H: 5.83%
C: 5.1%
publication car-t
Panbela to Host Third Quarter 2023 Earnings Conference Call on November 9, 2023
Published: 2023-10-24 (Crawled : 12:00) - globenewswire.com
PBLA | $0.4895 66K
|
Professional, Scientific, and T...
|
| O: -0.6%
H: 3.66%
C: 3.6%
conference
Panbela Announces Issuance of New Patent in China for Claims of a Novel Process for the Production of SBP-101Patent developed in collaboration with Syngene International Ltd.
Published: 2023-09-26 (Crawled : 13:00) - biospace.com/
PBLA | $0.4895 66K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 9.6%
C: 2.4%
sbp-101 patent international collaboration china
Gainers vs Losers
| 71% | 29% |
Top 10 Gainers
AGBA | News | $1.27 217.5% 120M
|
Finance
EGOX | $0.0503 39.72% 320M
|
RWOD | $10.52 31.56% 5.9M
|
n/a
ZCMD | $1.905 31.38% 30M
|
Commercial Services
MRDB 4 | $0.536 27.65% 2M
|
n/a
BSFC | $0.0822 27.64% 75M
|
Manufacturing
TPET | $0.4121 25.68% 45M
|
n/a
NVFY | $2.65 25.59% 33M
|
Consumer Durables
INDO | $5.1 25.0% 15M
|
Energy Minerals
CHRO | $1.53 24.9% 100K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.